Body image appearance in Parkinson's disease patients on device aided therapies.

Ahead of Print

Publisher: Springer-Verlag Italia Country of Publication: Italy NLM ID: 100959175 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1590-3478 (Electronic) Linking ISSN: 15901874 NLM ISO Abbreviation: Neurol Sci Subsets: MEDLINE

Original Publication: Milano, Italy : Springer-Verlag Italia, c2000-

Introduction: Parkinson's disease patients may experience altered body image perception. Advanced Parkinson's disease (aPD) with motor complications often requires surgical and device-aided treatments (DAT), such as levodopa-carbidopa intestinal gel (LCIG) and deep brain stimulation (DBS). Understanding body image perception is crucial when managing these devices. This study aims to explore body image perception in aPD patients, hypothesizing a link between DAT and body image perception.
Methods: We performed a cross-sectional study including non-demented aPD patients with and without DAT and age- and sex-matched controls. Participants were assessed using the Appearance Schemas Inventory-Revised (ASI-R), including Motivational Salience (MS) and Self-Evaluative Salience (SES) scores. Additional data included age, education, BMI, comorbidities, pharmacotherapy, and psychopathologies. PD patients were also evaluated with UPDRS, Hoehn and Yahr scales and LEDD calculation.
Results: 70 aPD and 36 controls were enrolled. No differences in ASI-R scores were found between PD patients and controls, but women with PD had significantly lower MS scores than controls (16.1 ± 5.6 vs 19.7 ± 5.8; p = 0.023). Among aPD patients, those on DAT had longer disease duration, higher Hoehn and Yahr, and lower UPDRS IV scores. The lowest MS was observed in women on LCIG (12.7 ± 3.3; p = 0.001).
Discussion: This study shows low MS ratings driven by female gender and LCIG treatment. Women on LCIG show reduced attention and management of their appearance. This may be influenced by cultural, environmental, and biological factors. Prospective research is needed to understand the impact of DAT on body image.
(© 2024. Fondazione Società Italiana di Neurologia.)

Dijk JM, Espay AJ, Katzenschlager R, de Bie RMA (2020) The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When? J Parkinsons Dis 10(s1):S65–S73. https://doi.org/10.3233/JPD-202104. (PMID: 10.3233/JPD-202104326513337592668)
de Bie RMA, Clarke CE, Espay AJ, Fox SH, Lang AE (2020) Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how. Lancet Neurol 19(5):452–461. https://doi.org/10.1016/S1474-4422(20)30036-3. (PMID: 10.1016/S1474-4422(20)30036-332171387)
Kim HJ, Mason S, Foltynie T, Winder-Rhodes S, Barker RA, Williams-Gray CH (2020) Motor complications in Parkinson’s disease: 13-year follow-up of the CamPaIGN cohort. Mov Disord 35(1):185–190. https://doi.org/10.1002/mds.27882. (PMID: 10.1002/mds.2788231965629)
Prange S, Klinger H, Laurencin C, Danaila T, Thobois S (2022) Depression in Patients with Parkinson’s Disease: Current Understanding of its Neurobiology and Implications for Treatment. Drugs Aging 39(6):417–439. https://doi.org/10.1007/s40266-022-00942-1. (PMID: 10.1007/s40266-022-00942-1357058489200562)
Gallagher DA, Lees AJ, Schrag A (2010) What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord 25(15):2493–2500. https://doi.org/10.1002/mds.23394. (PMID: 10.1002/mds.2339420922807)
Findley L, Eichorn T, Janca A, Kazenwadel J, Baker M , Currie-Gnjesda D, Koller W, Liebermann A, Mizuno Y, Rajput A, Roy S, Stocchi F, Tolosa E, Global Parkinson's Disease Survey (GPDS) Steering Committee (2002) Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 17(1):60–67. https://doi.org/10.1002/mds.10010.
Gamarra AH, Molski CS, Hilbig A, Valentini CK, Striebel VL, Rieder CR (2009) Evaluation of body image and self-concept and their correlation with depressive symptoms in Parkinson’s disease. Arq Neuropsiquiatr 67(3A):585–590. https://doi.org/10.1590/s0004-282x2009000400002. (PMID: 10.1590/s0004-282x200900040000219722032)
Sattin D, Parma C, Lunetta C, Zulueta A, Lanzone J, Giani L, Vassallo M, Picozzi M, Parati EA (2023) An Overview of the Body Schema and Body Image: Theoretical Models, Methodological Settings and Pitfalls for Rehabilitation of Persons with Neurological Disorders. Brain Sci 13(10):1410. https://doi.org/10.3390/brainsci13101410. (PMID: 10.3390/brainsci131014103789177910605253)
Stefani A, Tessitore A, Tambasco N, Cossu G, Ceravolo MG, Defazio G, Morgante F, Ramat S, Melzi G, Gualberti G, Merolla R, Onuk K, Lopiano L (2022) Criteria for identification of advanced Parkinson’s disease: the results of the Italian subgroup of OBSERVE-PD observational study. BMC Neurol 22(1):41. https://doi.org/10.1186/s12883-022-02554-z. (PMID: 10.1186/s12883-022-02554-z350904068796340)
VandenBos GR (2007) APA Dictionary of Psychology, American Psychological Association: Washington. DC, USA.
Cash TF, Labarge AS (1996) Development of the Appearance Schemas Inventory: A new cognitive body-image assessment. Cogn Ther Res 20(1):37–50. https://doi.org/10.1007/BF02229242. (PMID: 10.1007/BF02229242)
Cash TF, Melnyk SE, Hrabosky JI (2004) The assessment of body image investment: an extensive revision of the appearance schemas inventory. Int J Eat Disord 35(3):305–316. https://doi.org/10.1002/eat.10264. (PMID: 10.1002/eat.1026415048946)
Toosi M (2016) Self-evaluative salience and motivational salience as predictors of depressive affect and appearance based rejection sensitivity. Walden University. https://scholarworks.waldenu.edu/cgi/viewcontent.cgi?article=3489&context=dissertations.
Jakatdar TA, Cash TF, Engle EK (2006) Body-image thought processes: The development and initial validation of the Assessment of Body-Image Cognitive Distortions. Body Image 3(4):325–333. https://doi.org/10.1016/j.bodyim.2006.09.001. (PMID: 10.1016/j.bodyim.2006.09.00118089236)
Linn BS, Linn MW, Gurel L (1968) Cumulative illness rating scale. J Am Geriatr Soc 16(5):622–626. https://doi.org/10.1111/j.1532-5415.1968.tb02103.x. (PMID: 10.1111/j.1532-5415.1968.tb02103.x5646906)
Derogatis LR, Savitz KL (1999) The SCL-90-R, Brief Symptom Inventory, and Matching Clinical Rating Scales. In: Maruish ME (ed) The use of psychological testing for treatment planning and outcomes assessment, 2nd edn. Lawrence Erlbaum Associates Publishers, New Jersey, pp 679–724.
Marano M, Pilotto A, Padovani A, Gupta D, Vivacqua G, Magliozzi A, Di Lazzaro V, Carta M, Meloni M (2024) The chronic use of serotonin norepinephrine reuptake inhibitors facilitates dyskinesia priming in early Parkinson’s disease. J Neurol 271(7):3711–3720. https://doi.org/10.1007/s00415-024-12400-6. (PMID: 10.1007/s00415-024-12400-638720139)
Bissolotti L, Isacco-Grassi F, Orizio C, Gobbo M, Berjano P, Villafañe JH, Negrini S (2015) Spinopelvic balance and body image perception in Parkinson’s disease: analysis of correlation. Eur Spine J 24(Suppl 7):898–905. https://doi.org/10.1007/s00586-015-4265-7. (PMID: 10.1007/s00586-015-4265-726441255)
Gawlik NR, Elias AJ, Bond MJ (2016) Appearance Investment, Quality of Life, and Metabolic Control Among Women with Type 1 Diabetes. Int J Behav Med 23(3):348–354. https://doi.org/10.1007/s12529-015-9524-9. (PMID: 10.1007/s12529-015-9524-926582422)
Casale S, Pettini C, Fioravanti G, Padovani M, Ghinassi S (2024) The Link Between Problematic Instagram Use and Body-Image Investment Dimensions: The Meanting Role of Social Comparison on Instagram and the Need to Conceal Body Flaws. Clin Neuropsychiatry 21(1):79–87. https://doi.org/10.36131/cnfioritieditore20240105. (PMID: 10.36131/cnfioritieditore202401053855942910979791)
Marano M, Altavista MC, Cassetta E, Brusa L, Viselli F, Denaro A, Ventriglia M, Peppe A (2024) The influence of sex on non-motor wearing-off in Parkinson’s disease: A WORK-PD post-hoc study. Neurosci Lett 836:137850. https://doi.org/10.1016/j.neulet.2024.137850. (PMID: 10.1016/j.neulet.2024.13785038852765)
Moes HR, Groenendal-Laurensse JWMJ, Drent M, Tissingh G, van Laar T (2020) Predictors of Time to Discontinuation of Levodopa-Carbidopa Intestinal Gel Infusion: A Retrospective Cohort Study. J Parkinsons Dis 10(3):935–944. https://doi.org/10.3233/JPD-201978. (PMID: 10.3233/JPD-201978326754207458507)
Garrì F, Russo FP, Carrer T, Weis L, Pistonesi F, Mainardi M, Sandre M, Savarino E, Farinati F, Del Sorbo F, Soliveri P, Calandrella D, Biundo R, Carecchio M, Zecchinelli AL, Pezzoli G, Antonini A (2022) Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson’s disease on levodopa/carbidopa intestinal gel infusion. J Neurol 269(10):5606–5614. https://doi.org/10.1007/s00415-022-11269-7. (PMID: 10.1007/s00415-022-11269-7358768759309989)
Cerroni R, Scalise S, Imbriani P, Liguori C, Pierantozzi M, Pisani A, Mercuri NB, Stefani A (2020) Compliance with levodopa-carbidopa intestinal gel in a selected population in central south Italy: Beyond sex, a possible gender effect. Parkinsonism Relat Disord 73:57–59. https://doi.org/10.1016/j.parkreldis.2020.03.024. (PMID: 10.1016/j.parkreldis.2020.03.02432276132)
Angulo J, Fleury V, Péron JA, Penzenstadler L, Zullino D, Krack P (2019) Shame in Parkinson’S Disease: A Review. J Parkinsons Dis 9(3):489–499. https://doi.org/10.3233/JPD-181462. (PMID: 10.3233/JPD-181462310817926700625)
Gualdi-Russo E, Rinaldo N, Masotti S, Bramanti B, Zaccagni L (2022) Sex Differences in Body Image Perception and Ideals: Analysis of Possible Determinants. Int J Environ Res Public Health 19(5):2745. https://doi.org/10.3390/ijerph19052745. (PMID: 10.3390/ijerph19052745352704368910708)
Assogna F, Pellicano C, Savini C, Macchiusi L, Pellicano GR, Alborghetti M, Caltagirone C, Spalletta G, Pontieri FE (2020) Drug Choices and Advancements for Managing Depression in Parkinson’s Disease. Curr Neuropharmacol 18(4):277–287. https://doi.org/10.2174/1570159X17666191016094857. (PMID: 10.2174/1570159X17666191016094857316222077327944)
Deuschl G, Antonini A, Costa J, Śmiłowska K, Berg D, Corvol JC, Fabbrini G, Ferreira J, Foltynie T, Mir P, Schrag A, Seppi K, Taba P, Ruzicka E, Selikhova M, Henschke N, Villanueva G, Moro E (2022) European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson’s disease: I Invasive therapies. Eur J Neurol 29(9):2580–2595. https://doi.org/10.1111/ene.15386. (PMID: 10.1111/ene.1538635791766)

Keywords: Body appearance; Deep brain stimulation; Infusion therapies; Levodopa carbidopa intestinal gel; Motor fluctuation

Date Created: 20240913 Latest Revision: 20240913

20240914

10.1007/s10072-024-07753-9

39269573